Skip to main content
main-content

13.02.2019 | Original Paper | Ausgabe 5/2019

Acta Neuropathologica 5/2019

Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA

Zeitschrift:
Acta Neuropathologica > Ausgabe 5/2019
Autoren:
Yanghao Hou, Jorge Pinheiro, Felix Sahm, David E. Reuss, Daniel Schrimpf, Damian Stichel, Belén Casalini, Christian Koelsche, Philipp Sievers, Annika K. Wefers, Annekathrin Reinhardt, Azadeh Ebrahimi, Francisco Fernández-Klett, Stefan Pusch, Jochen Meier, Leonille Schweizer, Werner Paulus, Marco Prinz, Christian Hartmann, Karl H. Plate, Guido Reifenberger, Torsten Pietsch, Pascale Varlet, Mélanie Pagès, Ulrich Schüller, David Scheie, Karin de Stricker, Stephan Frank, Jürgen Hench, Bianca Pollo, Sebastian Brandner, Andreas Unterberg, Stefan M. Pfister, David T. W. Jones, Andrey Korshunov, Wolfgang Wick, David Capper, Ingmar Blümcke, Andreas von Deimling, Luca Bertero
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00401-019-01969-2) contains supplementary material, which is available to authorized users.
Yanghao Hou, Jorge Pinheiro, Andreas von Deimling, Luca Bertero contributed equally.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Papillary glioneuronal tumor (PGNT) is a WHO-defined brain tumor entity that poses a major diagnostic challenge. Recently, SLC44A1PRKCA fusions have been described in PGNT. We subjected 28 brain tumors from different institutions histologically diagnosed as PGNT to molecular and morphological analysis. Array-based methylation analysis revealed that 17/28 tumors exhibited methylation profiles typical for other tumor entities, mostly dysembryoplastic neuroepithelial tumor and hemispheric pilocytic astrocytoma. Conversely, 11/28 tumors exhibited a unique profile, thus constituting a distinct methylation class PGNT. By screening the extended Heidelberg cohort containing over 25,000 CNS tumors, we identified three additional tumors belonging to this methylation cluster but originally histologically diagnosed otherwise. RNA sequencing for the detection of SLC44A1PRKCA fusions could be performed on 19 of the tumors, 10 of them belonging to the methylation class PGNT. In two additional cases, SLC44A1PRKCA fusions were confirmed by FISH. We detected fusions involving PRKCA in all cases of this methylation class with material available for analyses: the canonical SLC44A1PRKCA fusion was observed in 11/12 tumors, while the remaining case exhibited a NOTCH1-PRKCA fusion. Neither of the fusions was found in the tumors belonging to other methylation classes. Our results point towards a high misclassification rate of the morphological diagnosis PGNT and clearly demonstrate the necessity of molecular analyses. PRKCA fusions are highly diagnostic for PGNT, and detection by RNA sequencing enables the identification of rare fusion partners. Methylation analysis recognizes a unique methylation class PGNT irrespective of the nature of the PRKCA fusion.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 5/2019

Acta Neuropathologica 5/2019 Zur Ausgabe
  1. Sie können e.Med Neurologie & Psychiatrie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Sie können e.Med Neurologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.